Incident heart failure and myocardial infarction in sodium‐glucose cotransporter‐2 vs. dipeptidyl peptidase‐4 inhibitor users-Reference-Cited by-同舟云学术

Incident heart failure and myocardial infarction in sodium‐glucose cotransporter‐2 vs. dipeptidyl peptidase‐4 inhibitor users

Published:2022-02-07 Issue:2 Volume:9 Page:1388-1399
ISSN:2055-5822
Container-title:ESC Heart Failure
language:en
Short-container-title:ESC Heart Failure

Author:

Zhou Jiandong¹,Lee Sharen²^ORCID,Leung Keith Sai Kit³,Wai Abraham Ka Chung³,Liu Tong⁴,Liu Ying⁵,Chang Dong⁶,Wong Wing Tak⁷,Wong Ian Chi Kei⁸,Cheung Bernard Man Yung⁹,Zhang Qingpeng¹⁰,Tse Gary²⁴⁵¹¹^ORCID

Affiliation:

1. Nuffield Department of Medicine University of Oxford Oxford UK

2. Diabetes Research Unit Cardiovascular Analytics Group Hong Kong China

3. Emergency Medicine Unit, Faculty of Medicine The University of Hong Kong Hong Kong China

4. Tianjin Key Laboratory of Ionic‐Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin China

5. Department of Cardiology The First Affiliated Hospital of Dalian Medical University Dalian China

6. Xiamen Cardiovascular Hospital Xiamen University Xiamen China

7. School of Life Sciences, State Key Laboratory of Agrobiotechnology (CUHK) The Chinese University of Hong Kong Hong Kong China

8. Department of Pharmacology and Pharmacy University of Hong Kong Hong Kong China

9. Division of Clinical Pharmacology and Therapeutics, Department of Medicine The University of Hong Kong Hong Kong China

10. School of Data Science City University of Hong Kong Hong Kong China

11. Kent and Medway Medical School Canterbury Kent UK

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ehf2.13830

Reference35 articles.

1. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications

2. Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017

3. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis

4. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis

5. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Control for multiple risk factors and incident heart failure and mortality in patients with diabetes mellitus: Insights from the Kailuan cohort study;Current Problems in Cardiology;2024-09

2. Deciphering mortality risk of diabetes medications in heart failure patients with diabetes mellitus under triple guideline-directed medical therapy;International Journal of Cardiology;2024-07

3. Numbers Needed to Treat for Preventing Adverse Cardiovascular Outcomes for Sodium-Glucose Cotransporter 2 Inhibitors vs. Dipeptidyl Peptidase 4 Inhibitors: The Hong Kong Diabetes Study;Cardiovascular Drugs and Therapy;2024-01-20

4. Progression and identification of heart disease risk factors in diabetic patients from electronic health records;Internet of Things and Machine Learning for Type I and Type II Diabetes;2024

5. New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study;European Heart Journal - Cardiovascular Pharmacotherapy;2023-11-14